


above-captioned 35 U.S.C. 371 national application. Accordingly, no new matter is added, and entry of the amendment is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: February 11, 2002



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

RECEIVED

MAY 03 2002

Attorney Docket No.: 5559.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re Application of: Bojsen et al.

Serial No.: 09/856,819

Confirmation No: To Be Assigned

Group Art Unit: To Be Assigned

Filed: May 24, 2001

Examiner: To Be Assigned

For: Lipolytic Enzyme Variants

RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

Below is a marked-up version of the amendments made in the accompanying amendment.

IN THE SPECIFICATION:

The paragraph under the heading "CROSS-REFERENCE TO RELATED APPLICATIONS" has been amended as follows:

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. 371 national application of PCT/DK99/00664, filed November 29, 1999, and claims, under 35 U.S.C. 119, priority of Danish application nos. PA 1998 01572, filed November 27, 1998, [PA 1998 01573, filed November 27, 1998,] PA 1999 00391, filed March 22, 1999, PA 1999 01481, filed October 15, 1999, and the benefit under 35 U.S.C. 119(e) of United States provisional patent application nos. 60/111,430, filed on December 8, 1998, 60/126,914, filed on March 29, 1999, and 60/160,735, filed on October 22, 1999, the contents of which are fully incorporated herein by reference.--